Staff editor
The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis.
Philippe Langella, Research Director at the French National Institute of Agricultural Research, discussed the potential of Faecalibacterium Prausnitzii as Live Biotherapeutics for several disease.
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x.
MAP 315, is a novel live biotherapeutic product being developed for the treatment of ulcerative colitis and was discovered and developed using Microba’s data-driven Therapeutics Platform.
Together with Professor Lorenzo Morelli we focused on the significant role of diet and the microbiome in terms of health benefits, food production, and agri-industry systems.
Biofarma Group's R&D to support people in the pre-depressive phase.
Ensemble No.3 (ENS-003) is in development to address vulvovaginal candidiasis – a vaginal yeast infection for which antifungal treatments offer limited protection from recurrence.
Microbiomepost interviewed Lorenzo Drago, from University of Milan, during the ESGE DAYS congress, held recently in Dublin.
A large Korean population study provides scientific evidence that altering the gut microbiome composition through dietary habit change can help prevent and manage the hypertension.
Industry
Sponsored by
The 6’-SL HMO from Chr. Hansen is approved for highest use levels in infant formula and follow-on formula in EU.
